These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24902520)

  • 21. FDA notifications. Updated Atripla label approved.
    AIDS Alert; 2010 Mar; 25(3):36. PubMed ID: 20629262
    [No Abstract]   [Full Text] [Related]  

  • 22. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals.
    Scourfield A; Zheng J; Chinthapalli S; Waters L; Martin T; Mandalia S; Nelson M
    AIDS; 2012 Jul; 26(11):1399-401. PubMed ID: 22441251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.
    Gupta SK; Mi D; Moe SM; Dubé MP; Liu Z
    J Acquir Immune Defic Syndr; 2013 Nov; 64(3):279-83. PubMed ID: 24278992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The making of the one pill-Developing single tablet regimens for HIV and for HCV.
    Yang T; Oliyai R; Kent KM
    Antivir Ther; 2022 Apr; 27(2):13596535211067606. PubMed ID: 35491563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
    Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
    Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rilpivirine and complera: new first-line treatment options.
    O'Neal R
    BETA; 2011; 23(4):14-8. PubMed ID: 22567823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
    N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.
    Beck EJ; Mandalia S; Sangha R; Youle M; Brettle R; Gompels M; Johnson M; Pozniak A; Schwenk A; Taylor S; Walsh J; Wilkins E; Williams I; Gazzard B;
    PLoS One; 2012; 7(10):e47376. PubMed ID: 23118869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.
    Pozniak A; Markowitz M; Mills A; Stellbrink HJ; Antela A; Domingo P; Girard PM; Henry K; Nguyen T; Piontkowsky D; Garner W; White K; Guyer B
    Lancet Infect Dis; 2014 Jul; 14(7):590-9. PubMed ID: 24908550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis of adherence and efficiency when replacing an antiretroviral therapy with efavirenz-emtricitabine-tenofovir in a single daily dose].
    García-Ramos SE; Santolaya Perrín MR; Fernández-Pacheco García-Valdecasas M
    Farm Hosp; 2012; 36(5):315-20. PubMed ID: 22858089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy and tolerability of antiretroviral therapy containing tenofovir disoproxil fumarate-emtricitabine-efavirenz in treatment-naive patients infected with HIV-1 in Bobo Dioulasso (Burkina Faso, 2009-2011)].
    Zoungrana J; Hema A; Bado G; Poda GE; Kamboulé EB; Kaboré FN; Soré I; Sawadogo AB
    Bull Soc Pathol Exot; 2013 Oct; 106(4):239-43. PubMed ID: 24136661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
    Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
    J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.
    McCormack S; Fidler S; Fisher M; ;
    Int J STD AIDS; 2012 Jan; 23(1):1-4. PubMed ID: 22362679
    [No Abstract]   [Full Text] [Related]  

  • 37. [HIV therapy and adherence].
    Kuhlmann B
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():62-3. PubMed ID: 19024920
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
    Tan DH; Chan K; Raboud J; Cooper C; Montaner JS; Walmsley S; Hogg RS; Klein MB; Machouf N; Rourke SB; Tsoukas C; Loutfy MR;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):38-46. PubMed ID: 21709570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients.
    Calza L; Vanino E; Salvadori C; Manfredi R; Colangeli V; Cascavilla A; Di Bari MA; Motta R; Viale P
    HIV Clin Trials; 2014; 15(1):1-13. PubMed ID: 24518210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent FDA approvals and changes.
    AIDS Patient Care STDS; 2010 Feb; 24(2):133-4. PubMed ID: 20156092
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.